Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.57 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | DRD4 | P21917 | 3/20 | 0.56 |
| ▸ | DRD3 | P35462 | 3/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.54 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21071819 | 1.00 | CARM1 (0.57) | CARM1PRMT6DRD2DRD4DRD3 | |
| SCHEMBL19852044 | 1.00 | CARM1 (0.57) | CARM1PRMT6DRD2DRD4DRD3 | |
| SCHEMBL14038330 | 0.83 | HTR1A (0.69) | HTR1A | |
| SCHEMBL18070205 | 0.82 | HRH3 (0.49) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL19838566 | 0.81 | CARM1 (0.58) | CARM1PRMT6DRD2DRD4DRD3 | |
| SCHEMBL21071650 | 0.81 | CARM1 (0.58) | CARM1PRMT6DRD2DRD4DRD3 | |
| SCHEMBL19852209 | 0.81 | CARM1 (0.58) | CARM1PRMT6DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL19838785 | 0.80 | CARM1 (0.56) | CARM1PRMT6DRD2DRD4DRD3 | |
| SCHEMBL19838623 | 0.79 | CARM1 (0.66) | CARM1PRMT6DRD2DRD4DRD3 | |
| SCHEMBL11065075 | 0.79 | SLC6A4 (0.49) | GRIN2DGRIN3BADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | CARM1 3839/4885PRMT6 3548/4885DRD2 69/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | CARM1 3839/4885PRMT6 3548/4885DRD2 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.